This is an aggregated industry headline. Read the full story at BioPharma Dive →
FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services
Replimune's application is the latest example of changing attitudes at the FDA. Elsewhere, Revolution Medicines outlined more RAS-blocking data and a Definium stock offering brought in $800 million.
By BioPharma Dive
· Jun 26, 2026
· via BioPharma Dive
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
The agency spotted seven observations at Dr. Reddy's Bachupally, Hyderabad, biologics plant following a mid-Ju…
The WeekFierceBiotech ↗
As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial tea…
The WeekBriefing
The European Commission has launched formal antitrust proceedings into Sanofi’s flu vaccine marketing. The cas…